FDA Approves Novartis Kisqali^® to Reduce Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

Novartis announced that the US FDA has approved Kisqali® in combination with an aromatase inhibitor for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer at high risk of recurrence.